- Home
- PNI vs VANI Comparison
PNI vs VANI Comparison
Compare PNI & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNI | VANI |
|---|---|---|
| Founded | 2002 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.9M | 81.2M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PNI | VANI |
|---|---|---|
| Price | $6.87 | $1.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 26.4K | ★ 192.4K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.03 | $0.91 |
| 52 Week High | $7.89 | $1.92 |
Technical Indicators
Market Signals| Indicator | PNI | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 42.61 | 39.16 |
| Support Level | $6.82 | $1.36 |
| Resistance Level | $6.94 | $1.46 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 27.15 | 6.67 |
Price Performance
Historical ComparisonAbout PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.